PERSPECTA

News from every angle

← Back to headlines

AstraZeneca Licenses Lung Cancer Drug from China's Dizal Pharmaceutical for $1.5 Billion

AstraZeneca has entered into a $1.5 billion licensing agreement with China's Dizal Pharmaceutical for a lung cancer drug. This deal expands AstraZeneca's oncology portfolio with a new therapeutic candidate.

PostShare

Sources

Showing 0 of 2 sources

No articles available in your preferred languages.

2 articles available in other languages below.

seeking-alphaDanish25d ago

AstraZeneca inks $1.5B license deal for lung cancer drug

Read full article →
YahooSpanish25d ago

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Read full article →

Coverage Timeline

First report: Yahoo · 14 Jul, 06:19Full coverage: 2 · 2hWindow: 2h
Left-leaningCenterRight-leaning
Yahoo14 Jul, 06:19First to report

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

2h later
seeking-alpha14 Jul, 08:13Latest update

AstraZeneca inks $1.5B license deal for lung cancer drug

Related Stories

Nigeria and China Deepen Agricultural Partnership

11m ago

US Senate's Russia Sanctions Bill Faces Hurdles

30m ago

Pagadian's 'Salt Sisters' Revive Traditional Salt Industry

41m ago

After-Tax Portfolio Income Comparison: Florida vs. New York

49m ago